MDxHealth S.A.
MDxHealth S.A. (MDXH) Financial Performance & Income Statement Overview
Analyze MDxHealth S.A. (MDXH) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
MDxHealth S.A. (MDXH) Income Statement & Financial Overview
Explore comprehensive income reports for MDxHealth S.A. MDXH, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $24.74M | $23.32M | $22.16M | $19.83M |
| Cost of Revenue | $9.22M | $9.04M | $8.87M | $8.90M |
| Gross Profit | $15.52M | $14.28M | $13.29M | $10.94M |
| Gross Profit Ratio | $0.63 | $0.61 | $0.60 | $0.55 |
| R&D Expenses | $2.79M | $2.70M | $2.90M | $2.16M |
| SG&A Expenses | $15.57M | $16.35M | $16.48M | $15.39M |
| Operating Expenses | $20.13M | $20.37M | $20.70M | $17.55M |
| Total Costs & Expenses | $29.35M | $29.41M | $29.58M | $26.45M |
| Interest Income | $0.00 | $197000.00 | $222000.00 | $1.91M |
| Interest Expense | $0.00 | $4.96M | $1.39M | $1.91M |
| Depreciation & Amortization | $2.19M | $2.15M | $1.80M | $1.90M |
| EBITDA | -$2.42M | -$3.75M | -$5.62M | -$4.70M |
| EBITDA Ratio | -$0.10 | -$0.16 | -$0.25 | -$0.24 |
| Operating Income | -$4.61M | -$6.09M | -$7.42M | -$6.61M |
| Operating Income Ratio | -$0.19 | -$0.26 | -$0.33 | -$0.33 |
| Other Income/Expenses (Net) | -$2.19M | -$4.76M | -$4.11M | -$1.91M |
| Income Before Tax | -$6.79M | -$10.86M | -$11.53M | -$8.51M |
| Income Before Tax Ratio | -$0.27 | -$0.47 | -$0.52 | -$0.43 |
| Income Tax Expense | $48000.00 | $334000.00 | $0.00 | $1.86M |
| Net Income | -$6.84M | -$11.19M | -$11.53M | -$8.51M |
| Net Income Ratio | -$0.28 | -$0.48 | -$0.52 | -$0.43 |
| EPS | -$0.14 | -$0.40 | -$0.42 | -$0.31 |
| Diluted EPS | -$0.14 | -$0.24 | -$0.42 | -$0.31 |
| Weighted Avg Shares Outstanding | $48.86M | $27.97M | $27.29M | $27.29M |
| Weighted Avg Shares Outstanding (Diluted) | $48.86M | $47.29M | $27.29M | $27.29M |
Over the last four quarters, MDxHealth S.A. achieved steady financial progress, growing revenue from $19.83M in Q1 2024 to $24.74M in Q4 2024. Gross profit stayed firm with margins at 63% in Q4 2024 versus 55% in Q1 2024. Operating income totaled -$4.61M in Q4 2024, maintaining a -19% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$2.42M. Net income rose to -$6.84M, with EPS at -$0.14. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan